About GPO   |   Newsroom/Media   |   Congressional Relations   |   Inspector General   |   Careers   |   Contact   |   askGPO   |   Help  
 
Home   |   Customers   |   Vendors   |   Libraries  

The Electronic Code of Federal Regulations (e-CFR) is a regularly updated, unofficial editorial compilation of CFR material and Federal Register amendments produced by the National Archives and Records Administration's Office of the Federal Register (OFR) and the Government Printing Office.

Parallel Table of Authorities and Rules for the Code of Federal Regulations and the United States Code
Text | PDF

Find, review, and submit comments on Federal rules that are open for comment and published in the Federal Register using Regulations.gov.

Purchase individual CFR titles from the U.S. Government Online Bookstore.

Find issues of the CFR (including issues prior to 1996) at a local Federal depository library.

[2]
 
 

Electronic Code of Federal Regulations

blue pill

e-CFR Data is current as of April 16, 2014

TITLE 21—Food and Drugs

CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED)

SUBCHAPTER D—DRUGS FOR HUMAN USE

PART 330—OVER-THE-COUNTER (OTC) HUMAN DRUGS WHICH ARE GENERALLY RECOGNIZED AS SAFE AND EFFECTIVE AND NOT MISBRANDED

rule

Subpart A—GENERAL PROVISIONS

§330.1
General conditions for general recognition as safe, effective and not misbranded.
§330.2
Pregnancy-nursing warning.
§330.3
Imprinting of solid oral dosage form drug products.
§330.5
Drug categories.
rule

Subpart B—ADMINISTRATIVE PROCEDURES

§330.10
Procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded, and for establishing monographs.
§330.11
NDA deviations from applicable monograph.
§330.12
Status of over-the-counter (OTC) drugs previously reviewed under the Drug Efficacy Study (DESI).
§330.13
Conditions for marketing ingredients recommended for over-the-counter (OTC) use under the OTC drug review.
§330.14
Additional criteria and procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded.


For questions or comments regarding e-CFR editorial content, features, or design, email ecfr@nara.gov.
For questions concerning e-CFR programming and delivery issues, email webteam@gpo.gov.